Abstract | BACKGROUND: METHODS: The level of EGFR ligands in human drain fluids (DFs) from OSCC resection and remote flap donor site were determined. A mouse model of microscopic residual OSCC was established and treated with cetuximab to measure tumor growth, survival, and cervical lymph node metastases. A mouse model of wound healing was also established to assess the effect of an EGFR antibody on the wound healing process. RESULTS: EGFR ligands are found in sites from OSCC resection. EGFR targeted therapy can delay tumor regrowth in a microscopic residual disease model of OSCC without significant effects on local wound healing. CONCLUSION: These results provide a strong rationale for clinical evaluation of this approach to treat patients with local-regionally advanced OSCC.
|
Authors | Daisuke Sano, Maria K Gule, David I Rosenthal, Diana Bell, Jeremy Yates, Adel K El-Naggar, Jeffrey N Myers |
Journal | Head & neck
(Head Neck)
Vol. 35
Issue 3
Pg. 321-8
(Mar 2013)
ISSN: 1097-0347 [Electronic] United States |
PMID | 22367702
(Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
|
Copyright | Copyright © 2012 Wiley Periodicals, Inc. |
Chemical References |
- Antibodies, Monoclonal, Humanized
- Antineoplastic Agents
- Cytokines
- ErbB Receptors
- Cetuximab
|
Topics |
- Animals
- Antibodies, Monoclonal, Humanized
(adverse effects, therapeutic use)
- Antineoplastic Agents
(therapeutic use)
- Blotting, Western
- Carcinoma, Squamous Cell
(drug therapy, surgery)
- Cetuximab
- Cytokines
- Disease Models, Animal
- ErbB Receptors
(antagonists & inhibitors)
- Humans
- Mice
- Mouth Neoplasms
(drug therapy, surgery)
- Neoplasm, Residual
- Postoperative Period
- Wound Healing
(drug effects)
|